drugset / Trial / NCT01462357

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

NCT01462357

Phase 3 Completed 1079 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered according to a 2-dose schedule at 0, 6 months or the standard 3-dose schedule of 0, 2, 6 months in 9-14 years old healthy females.

Timeline

Start
2011-11-21
Primary completion
2015-10-27
Completion
2015-10-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Cervarix Vaccine 0.5 ml Intramuscular
Subject Gardasil Vaccine 0.5 ml Intramuscular